Clinical trials recruiting for Prostatic Neoplasms
36
Recruiting trials
36
US states with sites
48
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 8 |
| Texas | 8 |
| California | 7 |
| Florida | 7 |
| Maryland | 6 |
| Michigan | 6 |
| Washington | 6 |
| Georgia | 5 |
| Massachusetts | 5 |
| Ohio | 5 |
| Tennessee | 5 |
| Virginia | 5 |
Top cities
New York, New York 7Houston, Texas 6Atlanta, Georgia 5Boston, Massachusetts 5Grand Rapids, Michigan 5Los Angeles, California 5Seattle, Washington 5Bethesda, Maryland 4Cleveland, Ohio 4Nashville, Tennessee 4
Self-screener
Recruiting trials
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of DM002 in Patients With Advanced Solid Tumors
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
- A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
- A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
- Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations
- Clinical Application of the J-PET Scanner Prototype
- Collection of Blood From Patients With Prostate Cancer
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
- Dose Escalation For INtraprostatic LEsions
- Evaluation of Different Methods of Ultrasound Image Analysis for Real-time Monitoring of HIFU Prostate Cancer Treatment
- Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
- Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation
- HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
- Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
- Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
- Institut Paoli Calmettes Prostate Cancer Database
- Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
- Lymphedema After Urologic Surgery
- Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
- Men at High Genetic Risk for Prostate Cancer
- Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- Prostate Active Surveillance Study
- Prostate Adaptive Radiation Therapy
- RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
Related conditions
Trials recruiting for Prostatic Neoplasms often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Prostatic Diseases 3Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Prostatic Neoplasms, Castration-Resistant 13Prostate Adenocarcinoma 52Metastatic Prostate Cancer 45Metastatic Hormone-Sensitive Prostate Cancer 8Metastatic Castration Resistant Prostate Cancer 67mCRPC 8
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Prostatic Neoplasms trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.